BR112017011623A2 - composições farmacêuticas e processo para a preparação de uma composição - Google Patents

composições farmacêuticas e processo para a preparação de uma composição

Info

Publication number
BR112017011623A2
BR112017011623A2 BR112017011623A BR112017011623A BR112017011623A2 BR 112017011623 A2 BR112017011623 A2 BR 112017011623A2 BR 112017011623 A BR112017011623 A BR 112017011623A BR 112017011623 A BR112017011623 A BR 112017011623A BR 112017011623 A2 BR112017011623 A2 BR 112017011623A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
compositions
population
composition
present
Prior art date
Application number
BR112017011623A
Other languages
English (en)
Inventor
Shah Abhishek
Bhasale Ketan
Jha Romesh
Das Subhasis
Kumar Thommandru Vijaya
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of BR112017011623A2 publication Critical patent/BR112017011623A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica que compreende duas populações diferentes com a primeira população compreendendo oseltamivir ou um sal farmaceuticamente aceitável do mesmo e um ou mais excipientes farmaceuticamente aceitáveis e a segunda população compreendendo um ou mais excipientes farmaceuticamente aceitáveis. de preferência, as composições da segunda população não contêm oseltamivir ou um sal farmaceuticamente aceitável do mesmo. a presente invenção também descreve um novo método de enchimento da composição no recipiente. os inventores da presente invenção verificaram, surpreendentemente, que as composições são estáveis em condições de estabilidade a longo prazo e em tempo real. além disso, as composições são bioequivalentes à formulação de suspensão de mercado de fosfato de oseltamivir.
BR112017011623A 2014-12-01 2015-11-30 composições farmacêuticas e processo para a preparação de uma composição BR112017011623A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1262KO2014 2014-12-01
PCT/IB2015/059198 WO2016088010A1 (en) 2014-12-01 2015-11-30 Oseltamivir compositions

Publications (1)

Publication Number Publication Date
BR112017011623A2 true BR112017011623A2 (pt) 2018-03-06

Family

ID=55069027

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011623A BR112017011623A2 (pt) 2014-12-01 2015-11-30 composições farmacêuticas e processo para a preparação de uma composição

Country Status (3)

Country Link
US (1) US20170258749A1 (pt)
BR (1) BR112017011623A2 (pt)
WO (1) WO2016088010A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302151A (zh) * 2019-07-16 2019-10-08 苏州二叶制药有限公司 含有磷酸奥司他韦的口服干混悬剂及其制备方法
CN111297823B (zh) * 2020-03-04 2021-06-18 石药集团中奇制药技术（石家庄）有限公司 一种磷酸奥司他韦胶囊的制备方法
CN112121027B (zh) * 2020-08-25 2023-01-17 北京民康百草医药科技有限公司 磷酸奥司他韦包衣颗粒的药物组合物、用途及制备方法
CN112494434A (zh) * 2020-12-17 2021-03-16 江苏万珺医药科技有限公司 含有磷酸奥司他韦的干混悬剂及其制备方法
CN112717137B (zh) * 2021-01-20 2022-12-30 澳美制药(苏州)有限公司 含有磷酸奥司他韦的药物组合物及其制备方法
CN115529815B (zh) * 2021-04-27 2024-04-30 广州共禾医药科技有限公司 经直肠施用的奥司他韦或其药学上可接受的盐的药物组合物、及其制备方法和用途
CN116211810A (zh) * 2023-03-21 2023-06-06 南京海鲸药业股份有限公司 一种磷酸奥司他韦干混悬剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763483A (en) 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
WO2007097325A1 (ja) * 2006-02-20 2007-08-30 Chugai Seiyaku Kabushiki Kaisha リン酸オセルタミビル含有医薬組成物
CN1820744B (zh) * 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
US20120093738A1 (en) * 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
CN103315965B (zh) * 2013-07-11 2015-08-05 河南中帅医药科技股份有限公司 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法
CN104138355A (zh) * 2014-08-06 2014-11-12 广东东阳光药业有限公司 一种磷酸奥司他韦干混悬剂及其制备方法

Also Published As

Publication number Publication date
WO2016088010A1 (en) 2016-06-09
US20170258749A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112017011623A2 (pt) composições farmacêuticas e processo para a preparação de uma composição
BR112018010018A2 (pt) moduladores de ror-gama
MX2017004631A (es) Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
CO2018002026A2 (es) Composiciones de insulina de rápida acción
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
MX2020005247A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
CO2020016582A2 (es) Sales de sepiapterina farmacéuticamente aceptables
BR112017009545B8 (pt) Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BR112017001860A2 (pt) peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
BR112018003617A2 (pt) adesivo não aquoso compreendendo lidocaína e método para administrar referido adesivo
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
CL2019000766A1 (es) Composiciones de éster de colina de ácido lipoico y métodos para estabilizar en productos farmacológicos farmacéuticamente relevantes.
MX2017012022A (es) Compuestos organicos.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
EA202091561A1 (ru) Фармацевтическая композиция, содержащая фармацевтически приемлемую кислотно-аддитивную соль леналидомида
BR112019023074A2 (pt) composição contendo ciclodextrina e bussulfano

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]